Since erythropoietin is primarily produced by renal cortical peritubular cells, effects of SGLT‐2 inhibition on anaemia could represent an example of systemic effects mediated by proximal tubule SGLT‐2 inhibition, independent of circulating glucose levels. Here, EPO is linked to anemia (phenotype).